Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2006 1
2007 1
2009 1
2010 2
2011 5
2012 5
2013 4
2014 2
2015 3
2016 3
2017 3
2018 2
2019 4
2020 2
2021 6
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

43 results
Results by year
Filters applied: . Clear all
Page 1
The role of the ALK receptor in cancer biology.
Hallberg B, Palmer RH. Hallberg B, et al. Ann Oncol. 2016 Sep;27 Suppl 3:iii4-iii15. doi: 10.1093/annonc/mdw301. Ann Oncol. 2016. PMID: 27573755 Free article. Review.
This review summarises the latest research on the receptor tyrosine kinase ALK, and how this information can guide the management of patients with cancer that is ALK-positive. ...This emphasises the need to tailor the sequence of ALK TKIs according to the …
This review summarises the latest research on the receptor tyrosine kinase ALK, and how this information can guide the management of …
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.
Hallberg B, Palmer RH. Hallberg B, et al. Nat Rev Cancer. 2013 Oct;13(10):685-700. doi: 10.1038/nrc3580. Nat Rev Cancer. 2013. PMID: 24060861 Review.
The common activation of ALK has led to the use of the ALK tyrosine kinase inhibitor (TKI) crizotinib in a range of patient populations and to the rapid development of second-generation drugs targeting ALK. In this Review, we discuss our current understanding …
The common activation of ALK has led to the use of the ALK tyrosine kinase inhibitor (TKI) crizotinib in a range of patient po …
ATR inhibition enables complete tumour regression in ALK-driven NB mouse models.
Szydzik J, Lind DE, Arefin B, Kurhe Y, Umapathy G, Siaw JT, Claeys A, Gabre JL, Van den Eynden J, Hallberg B, Palmer RH. Szydzik J, et al. Among authors: hallberg b. Nat Commun. 2021 Nov 24;12(1):6813. doi: 10.1038/s41467-021-27057-2. Nat Commun. 2021. PMID: 34819497 Free PMC article.
High-risk neuroblastoma (NB) often involves MYCN amplification as well as mutations in ALK. Currently, high-risk NB presents significant clinical challenges, and additional therapeutic options are needed. Oncogenes like MYCN and ALK result in increased replication s …
High-risk neuroblastoma (NB) often involves MYCN amplification as well as mutations in ALK. Currently, high-risk NB presents signific …
Targeting anaplastic lymphoma kinase in neuroblastoma.
Umapathy G, Mendoza-Garcia P, Hallberg B, Palmer RH. Umapathy G, et al. Among authors: hallberg b. APMIS. 2019 May;127(5):288-302. doi: 10.1111/apm.12940. Epub 2019 Apr 3. APMIS. 2019. PMID: 30803032 Free PMC article. Review.
An impressive array of tyrosine kinase inhibitors (TKIs) that act to inhibit ALK have been FDA approved for use in ALK-driven cancers. ALK TKIs bind differently within the ATP-binding pocket of the ALK kinase domain and have been associated with differ …
An impressive array of tyrosine kinase inhibitors (TKIs) that act to inhibit ALK have been FDA approved for use in ALK-driven …
ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation.
Borenäs M, Umapathy G, Lai WY, Lind DE, Witek B, Guan J, Mendoza-Garcia P, Masudi T, Claeys A, Chuang TP, El Wakil A, Arefin B, Fransson S, Koster J, Johansson M, Gaarder J, Van den Eynden J, Hallberg B, Palmer RH. Borenäs M, et al. Among authors: hallberg b. EMBO J. 2021 Feb 1;40(3):e105784. doi: 10.15252/embj.2020105784. Epub 2021 Jan 7. EMBO J. 2021. PMID: 33411331 Free PMC article.
ALK is activated by the ALKAL2 ligand located on chromosome 2p, along with ALK and MYCN, in the "2p-gain" region associated with NB. ...Therefore, we tested whether ALKAL2 ligand could potentiate NB progression in the absence of ALK mutation. We show that ALK
ALK is activated by the ALKAL2 ligand located on chromosome 2p, along with ALK and MYCN, in the "2p-gain" region associated wi
BioID-Screening Identifies PEAK1 and SHP2 as Components of the ALK Proximitome in Neuroblastoma Cells.
Uçkun E, Siaw JT, Guan J, Anthonydhason V, Fuchs J, Wolfstetter G, Hallberg B, Palmer RH. Uçkun E, et al. Among authors: hallberg b. J Mol Biol. 2021 Sep 17;433(19):167158. doi: 10.1016/j.jmb.2021.167158. Epub 2021 Jul 15. J Mol Biol. 2021. PMID: 34273398 Free article.
LC/MS-MS analysis identified multiple proteins, including PEAK1 and SHP2, which were validated as ALK interactors in NB cells. Further analysis of the ALK-SHP2 interaction confirmed that the ALK-SHP2 interaction as well as SHP2-Y542 phosphorylation was depend …
LC/MS-MS analysis identified multiple proteins, including PEAK1 and SHP2, which were validated as ALK interactors in NB cells. Furthe …
Anaplastic lymphoma kinase in human cancer.
Schonherr C, Hallberg B, Palmer R. Schonherr C, et al. Among authors: hallberg b. Crit Rev Oncog. 2012;17(2):123-43. doi: 10.1615/critrevoncog.v17.i2.10. Crit Rev Oncog. 2012. PMID: 22471704 Review.
The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase is now implicated in a wide range of human cancers. Results from recent clinical trials with ALK inhibitors provide promise for patients harboring oncogenic ALK lesions. ...
The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase is now implicated in a wide range of human cancers. Results from recent …
Loss of RET Promotes Mesenchymal Identity in Neuroblastoma Cells.
Siaw JT, Gabre JL, Uçkun E, Vigny M, Zhang W, Van den Eynden J, Hallberg B, Palmer RH, Guan J. Siaw JT, et al. Among authors: hallberg b. Cancers (Basel). 2021 Apr 15;13(8):1909. doi: 10.3390/cancers13081909. Cancers (Basel). 2021. PMID: 33921066 Free PMC article.
Aberrant activation of anaplastic lymphoma kinase (ALK) drives neuroblastoma (NB). Previous work identified the RET receptor tyrosine kinase (RTK) as a downstream target of ALK activity in NB models. We show here that ALK activation in response to ALKAL2 liga …
Aberrant activation of anaplastic lymphoma kinase (ALK) drives neuroblastoma (NB). Previous work identified the RET receptor tyrosine …
Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration.
Huang H, Gont A, Kee L, Dries R, Pfeifer K, Sharma B, Debruyne DN, Harlow M, Sengupta S, Guan J, Yeung CM, Wang W, Hallberg B, Palmer RH, Irwin MS, George RE. Huang H, et al. Among authors: hallberg b. Cell Rep. 2021 Jul 13;36(2):109363. doi: 10.1016/j.celrep.2021.109363. Cell Rep. 2021. PMID: 34260934 Free PMC article.
Although activating mutations of the anaplastic lymphoma kinase (ALK) membrane receptor occur in 10% of neuroblastoma (NB) tumors, the role of the wild-type (WT) receptor, which is aberrantly expressed in most non-mutated cases, is unclear. ...Here, we map the cleavage sit …
Although activating mutations of the anaplastic lymphoma kinase (ALK) membrane receptor occur in 10% of neuroblastoma (NB) tumors, th …
FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase.
Guan J, Umapathy G, Yamazaki Y, Wolfstetter G, Mendoza P, Pfeifer K, Mohammed A, Hugosson F, Zhang H, Hsu AW, Halenbeck R, Hallberg B, Palmer RH. Guan J, et al. Among authors: hallberg b. Elife. 2015 Sep 29;4:e09811. doi: 10.7554/eLife.09811. Elife. 2015. PMID: 26418745 Free PMC article.
Vertebrate ALK has been considered to be an orphan receptor and the identity of the ALK ligand(s) is a critical issue. Here we show that FAM150A and FAM150B are potent ligands for human ALK that bind to the extracellular domain of ALK and in addition t …
Vertebrate ALK has been considered to be an orphan receptor and the identity of the ALK ligand(s) is a critical issue. Here we …
43 results